We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

By LabMedica International staff writers
Posted on 05 May 2021
Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.

The clinical laboratory has gone through trial by fire in 2020, where total testing was 245% of baseline volumes, with ~55% being SARS-CoV-2 molecular tests. More...
Despite vaccines, many industry players suggest SARS-CoV-2 testing volumes would not be impacted in the near term, and the demand for COVID-19-related testing will continue through 2021 and potentially into 2022. This means that testing-volume pressure on labs is going to continue.

Labs of all sizes are facing the same challenges: shortage of laboratory technologists and technicians, historic financial pressures on hospitals and health systems, and physically and mentally exhausted laboratory professionals - a pre-pandemic problem that has since been exacerbated. However, the TLA solutions that cater to labs processing high-sample volumes are out of reach for smaller volume labs due to space requirements and infrastructure constraints.

With the DxA 5000 Fit, mid-sized labs can enjoy the same benefits as larger-volume lab. The DxA 5000 Fit’s comprehensive workflow automation reduces up to 80% of manual steps through pre-analytical, analytical and post-analytical automation, thereby conserving precious human resources to do higher-value clinical work. It offers intelligent routing with dynamically calculated route planning for rapid and consistent TAT, with STATs always prioritized to deliver results faster. Additionally, its flexible design can be adapted to meet a mid-volume lab's space and infrastructure constraints.

"At Beckman Coulter, we believe that medium-size labs should be able to leverage the benefits of automation to address their challenges. Just because your lab is not processing a higher number of samples, doesn't mean you have to sacrifice the benefits of intelligent laboratory automation and settle for a marginally automated workcell-plus solution," said Dr. Peter Soltani, senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "This is why we have launched DxA 5000 Fit, the first compact workflow automation solution that's the right fit for mid-volume labs because automation should be for all labs."



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.